Medical Literacy in TIA (Transient Ischemic Attack) Patients
NCT ID: NCT07040761
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2025-06-30
2025-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An important part of patient care is to teach them to recognize the symptoms suggestive of a stroke as well as the contributing factors, thus improving the medical literacy of patients.
The results of studies that have assessed medical literacy in France and Europe converge towards a rather low level.
Some studies have focused on stroke literacy in France. They show good knowledge of risk factors and the attitude to adopt in the event of a stroke, but recognition of symptoms remains problematic.
There is very little literature concerning knowledge of TIA in the general population and there are no studies concerning literacy in a population having presented with TIA.
The aim of this study is to evaluate the knowledge of patients who have presented with a TIA (and therefore at high cardiovascular risk) about this disease (risk factors, symptoms, severity, attitude to adopt in the event of symptoms), after their visit to the emergency room.
The investigators make the hypothesis that knowledge of TIA and its consequences will be rather low in this population of patient, even after a medical contact at the emergency room.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TIA
TIA patients diagnosed in the emergency department and sent to neurology day hospital for evaluation
Two medical questionnaires
Medical questionnaires delivered by hand and completed the same day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Two medical questionnaires
Medical questionnaires delivered by hand and completed the same day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient referred to neurology day hospital at the Pierre Wertheimer neurological hospital after first care in the emergency department
* Patient having been informed and having expressed his non-opposition
* Patient affiliate to a social security scheme
Exclusion Criteria
* History of stroke/TIA
* Patient who do not understand the French language
* Patient under legal protection, guardianship, curatorship, under judicial protection-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathis Labeylie, DR
Role: PRINCIPAL_INVESTIGATOR
Hospices Civils de Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pierre Wertheimer hospital
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A00239-40
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL25_0091
Identifier Type: -
Identifier Source: org_study_id